

**Supplementary table 1.** Baseline characteristics of the patients stratified by response at six months follow-up.

Variable	Non responders (n=156)	Responders (n=211)	P value
Age (years), mean $\pm$ SD	51.9 (15.2)	53.7 (15.1)	0.252
Age groups, n (%)			0.195
40>	35 (23.5)	40 (18.3)	
40-60	73 (49.0)	101 (49.5)	
60<	41 (27.5)	70 (32.1)	
Females, n (%)	124 (83.2)	177 (81.2)	0.679
BMI, mean $\pm$ SD	27.0 (6.9)	26.5 (5.2)	0.389
Work status:			0.807
Works regularly	24 (16.2)	35 (16.3)	
Part time work	21 (14.2)	32 (14.9)	
Unemployed/retired	97 (65.5)	142 (66.0)	
Other	6 (4.1)	6 (2.8)	
Driving a car, n (%)	92 (61.7)	139 (63.8)	0.309
Approved monthly dosage of cannabis $\leq$ 20 grams, n (%)	127 (85.2)	201 (92.2)	0.039
Previous experience with cannabis, n (%)	70 (41.0)	96 (44.0)	0.798
Cigarettes smokers, n (%)	58 (38.9)	79 (36.2)	0.527
Number of regularly used medications, median (i.q range)	5.0 (3.0-7.0)	5.0 (3.0-8.0)	0.747
Number of regularly used medications for fibromyalgia, median (i.q range)	1.0 (0.0-2.0)	1.0 (1.0-3.0)	0.507
Treatment indication:			0.558
Primary fibromyalgia, n (%)	116 (77.9)	167 (76.6)	
Cancer, n (%)	15 (10.1)	20 (9.2)	
PTSD, n (%)	9 (6.0)	13 (6.0)	
Other, n (%)	9 (6.0)	18 (8.3)	

Years of chronic pain, median (i.q)	8.0 (3.0-12.0)	7.0 (3.2-14.0)	0.889
Type of pain: Daily, n (%) Episodic , n(%)	128 (85.9) 21 (14.1)	192 (88.1) 26 (11.9)	0.634

BMI – body mass index, I.Q range – interquartile range, PTSD – post traumatic stress disorder

**Supplementary table 2.** Cannabis used by the patients.

Cannabis dominant species and classification	Strain name and Cannabinoids content (all contain CBN 0.9%)	Patients (%)	Utilization methods		
			Vaporizing or smoking	Oil	Solids
<b>THC rich –Indica</b>	Erez (THC 20%, CBD 1%)	173 (47.1)	73 (19.8)	39 (10.6)	6 (1.6)
	Dorit (THC 20%, CBD 1%)	62 (16.9)	25 (6.8)	0 (0.0)	1 (0.2)
	Or (THC 20%, CBD 1%)	16 (4.4)	16 (4.4)	0 (0.0)	0 (0.0)
	Eran Almog (THC 20%, CBD 1%)	9 (2.5)	9 (2.5)	0 (0.0)	0 (0.0)
	Barak (THC 20%, CBD 1%)	6 (1.6)	6 (1.6)	0 (0.0)	0 (0.0)
	Omer (THC 20%, CBD 1%)	5 (1.4)	5 (1.4)	0 (0.0)	0 (0.0)
	Tal (THC 20%, CBD 1%)	7 (1.9)	3 (0.8)	0 (0.0)	0 (0.0)
	Yasmin (THC 15%, CBD 0%)	8 (2.2)	3 (0.8)	0 (0.0)	1 (0.2)
<b>THC rich – Sativa</b>	Alaska (THC 20%, CBD 1%)	41 (11.2)	40 (11.0)	1 (0.2)	0 (0.0)
	Shira (THC 20%, CBD 1%)	7 (1.9)	7 (1.9)	0 (0.0)	0 (0.0)

<b>CBD rich – Indica</b>	Avidekel (THC 1%, CBD 18%)	110 (30.0)	20 (5.4)	31 (8.4)	4 (1.0)
<b>CBD rich – Sativa</b>	Raphael (THC 1%, CBD 20%)	19 (5.2)	15 (4.0)	0 (0.0)	2 (0.5)
<b>Equal THC &amp; CBD – Indica</b>	Midnight (THC 10%, CBD 12%)	123 (33.5)	51 (13.9)	3 (0.8)	4 (1.0)
	Al-Na (THC 10%, CBD 5%)	6 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)

Patient can use more than one strain.

THC – tetrahydrocannabinol, CBD – cannabidiol, CBN – cannabinol.

**Supplementary table 3.** Medical cannabis related adverse events after six months

Adverse event	Number of patients (N=239)*
Dizziness	19 (7.9)
Dry mouth	16 (6.7)
Nausea and vomiting	13 (5.4)
Hyperactivity	12 (5.0)
Psychoactive	11 (5.2)
Drowsiness	10 (4.2)
Increased appetite	9 (3.8)
Weakness	8 (3.3)
Poor concentration and memory	6 (2.5)
Cough	5 (2.1)
Headache	5 (2.1)
Drop of sugar level	4 (1.7)
Hallucinations	3 (1.3)
confusion and disorientation	1 (0.4)
Tremor	1 (0.4)

\*We included 211 who used cannabis at six months follow-up in addition to 28 patients who ceased cannabis before six months

**Supplementary table 4.** Symptom prevalence at intake and after six months

Symptoms	Change at 6 months			p value**
	Symptom* Disappeared	Improvement*	No change or Deterioration*	
Sleep problems, No. (%)	26 (13.5)	144 (75.0)	22 (11.4)	<0.001
Weakness, No. (%)	5 (4.9)	57 (56.4)	39 (38.6)	<0.001
Cognitive impairment, No. (%)	5 (21.7)	4 (17.4)	14 (60.9)	0.004
Spasticity, No. (%)	3 (2.4)	84 (69.4)	34 (28.0)	<0.001
Depression, No. (%)	2 (1.6)	101 (83.4)	18 (14.8)	<0.001
Anxiety, No. (%)	4 (3.5)	87 (77.0)	22 (19.4)	<0.001
Restlessness, No. (%)	6 (8.9)	58 (86.5)	3 (4.4)	<0.001
Dizziness, No. (%)	9 (12.7)	44 (62.0)	18 (25.3)	<0.001
Constipation, No. (%)	5 (8.3)	30 (50.0)	25 (41.6)	<0.001
Nausea, No. (%)	9 (17.0)	32 (60.4)	12 (22.6)	<0.001
Lack of appetite, No. (%)	12 (22.6)	34 (64.1)	7 (13.2)	<0.001
Drowsiness, No. (%)	1 (2.4)	26 (63.4)	14 (34.1)	<0.001

\*Presented in percentage per symptom

\*\*For symptom at intake vs. symptom improvement or disappearing at six months

**Supplementary table 5.** Changes in other drug regimens after six months of treatment with cannabis.

<b>Drug class at baseline</b>	<b>Number of patients who stopped</b>	<b>Number of patients who reduced the dose</b>	<b>Number of patients who did not change the dose</b>	<b>Number of patients who initiate or increased the dose</b>	<b>Unknown</b>	<b>p value<sup>®</sup></b>
Benzodiazepines (n=118)	14 (11.8)	10 (8.4)	42 (35.6)	1 (0.8)	51 (43.2)	<0.001
Opioid analgesics* (n=126)	18 (14.3)	10 (7.9)	39 (30.9)	3 (2.3)	56 (44.4)	<0.001
SSRI or SNRI (n=77)	6 (7.7)	4 (5.1)	31 (40.2)	1 (1.2)	35 (45.4)	1.000
TCA (n=40)	12 (30.0)	0 (0.0)	12 (30.0)	1 (2.5)	15 (37.5)	0.021
Neuropathic pain drugs** (n=114)	17 (14.9)	10 (8.7)	40 (35.0)	3 (2.6)	44 (38.6)	<0.001
NSAID's (n=67)	7 (10.4)	3 (4.4)	16 (23.9)	2 (2.9)	39 (58.2)	0.001
OTC <sup>†</sup> (n=85)	10 (11.7)	3 (3.5)	20 (23.5)	1 (1.1)	51 (60.0)	0.092

<sup>®</sup>For using drug at baseline vs. those who stopped or reduced drug dosage at six months

\* Includes: Morphine, Tramadol, Fentanyl, Oxycodone, Buprenorphine, Oxycodone-naloxone (Targin), Acetaminophen-Oxycodone (Percocet), Codeine-Caffeine-Paracetamol (Rokacet).

\*\* Includes: Pregabalin, Gabapentin, Amitriptyline.


<sup>†</sup> Includes: Paracetamol andDipyrone

SSRI – Selective Serotonin Reuptake Inhibitor; SNRI – Serotonin–Norepinephrine Reuptake Inhibitor. NSAIDS's - Non-Steroidal Anti-Inflammatory Drugs, TCA - Tricyclic antidepressant

**Supplementary table 6.** Study outcomes stratified by primary vs. secondary fibromyalgia

<i>Variable</i>	<i>Primary Fibromyalgia</i>			<i>Secondary Fibromyalgia</i>		
	<i>Baseline</i>	<i>Six months</i>	<i>P value</i>	<i>Baseline</i>	<i>Six months</i>	<i>P value</i>
<i>Pain intensity (0-10 VAS scale)</i>	9.0 (8.0-10.0)	5.0 (4.0-6.0)	<0.001	9.0 (8.0-10.0)	4.0 (3.0-6.0)	<0.001
<i>Quality of life (5 points Likert scale)</i>	2.0 (1.0-2.0)	4.0 (3.0-4.0)	<0.001	2.0 (1.0-2.25)	4.0 (4.0-4.0)	<0.001
<i>Multivariable Analysis</i>	<i>Odds Ratio</i>	<i>95% C.I</i>	<i>P value</i>	<i>Odds Ratio</i>	<i>95% C.I</i>	<i>P value</i>
<i>Age &gt; 60 years</i>	0.42	0.18-1.02	0.06	0.10	0.01-1.00	0.05
<i>Concerns about cannabis - prior to treatment initiation</i>	0.41	0.16-1.04	0.06	0.22	0.04-1.36	0.10
<i>Spasticity</i>	2.65	1.12-6.25	0.03	1.59	0.31-8.13	0.57
<i>Previous experience with cannabis</i>	3.25	1.20-8.80	0.02	0.41	0.04-4.69	0.47





Supplementary Figure 1. Quality of life components on a 5-points Likert scale at baseline and at six months of follow-up. \* $p < 0.05$  \*\* $p < 0.001$ .